Characterization of the Endogenous DAF-12 Ligand and Its Use as an Anthelmintic Agent in *Strongyloides stercoralis*

Zhu Wang¹, Mi Cheong Cheong¹, Jet Tsien², Heping Deng², Tian Qin², Jonathan D. C. Stoltzfus³, Tegegn G. Jaleta⁴, Xinshe Li⁴, James B. Lok⁴, Steven A. Kliewer^{1,5,*}, and David J. Mangelsdorf^{1,6,,*}

¹Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

²Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

³Department of Biology, Millersville University of Pennsylvania, Millersville, PA 17551, USA

⁴Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁵Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

⁶Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

*Correspondence: steven.kliewer@utsouthwestern.edu (S.A.K.),
davo.mango@utsouthwestern.edu (D.J.M.)

ABSTRACT

A prevalent feature of *Strongyloides stercoralis* is a life-long and potentially lethal infection that is due to the nematode parasite's ability to autoinfect and, thereby, self-replicate within its host. Here, we investigated the role of the parasite's nuclear receptor, *Ss*-DAF-12, in governing infection. We identified Δ^7 -DA as the endogenous *Ss*-DAF-12 ligand and elucidated the hormone's biosynthetic pathway. Genetic loss of function of the ligand's rate-limiting enzyme demonstrated that Δ^7 -DA synthesis is necessary for parasite reproduction, whereas its absence is required for development of infectious larvae. Availability of the ligand permits *Ss*-DAF-12 to function as an on/off switch governing autoinfection, making it vulnerable to therapeutic intervention. In a preclinical model of hyperinfection, pharmacologic activation of DAF-12 suppressed autoinfection and markedly reduced lethality. Moreover, when Δ^7 -DA was administered with ivermectin, the current but limited drug of choice for treating strongyloidiasis, the combinatorial effects of the two drugs resulted in a near cure of the disease.

INTRODUCTION

Strongyloidiasis is a neglected tropical disease caused by the nematode parasite, *Strongyloides stercoralis*. It is estimated to infect ~600 million people worldwide and is endemic in Africa, Asia, Latin America, and parts of the Caribbean, southern United States and Europe (Buonfrate et al., 2020). Because of the unique nature of its lifecycle, *S. stercoralis* infections are often life-long and up to 2.5% of these infections will progress to a hyperinfection syndrome that has a 90% mortality rate if untreated (Milder et al., 1981). Notably, such hyperinfections are often caused by administering glucocorticoids to otherwise asymptomatic patients (Milder et al., 1981). The lifecycle of *S. stercoralis* is atypical of most soil-transmitted helminths (Krolewiecki et al., 2013; Lok, 2007; Page et al., 2018) (Figure 1). Infective third stage larvae (L3i) are developmentally quiescent and reside in fecal-contaminated soil until they contact the host and penetrate the skin, a process that reactivates their development as L3+ larvae. In the host, the activated L3+ immediately begin feeding, and typically migrate to the lungs, enter the alimentary canal, and transit to the intestine where the stage 4 larvae (L4) mature into parasitic (P)-adult females (there are no parasitic males). The P-adult females reproduce asexually and generate rhabditiform, non-infectious stage 1 larvae (L1) progeny that can enter two alternate lifecycle routes, one in the external environment and one in the host. Post-parasitic L1 (PP-L1) enter the external environment by leaving the host with the feces. Under conditions that mimic the host intestine (e.g., 37° C), most PP-L1 develop as females directly into infectious filariform L3i (Albarqi et al., 2016). However, under favorable conditions (e.g., 22° C, high humidity) the majority of PP-L1 undergo a developmental switch and become free-living (FL) male and female larvae that eventually mature into FL-adults, which are morphologically distinct from parasitic

females and feed on soil microbes. The FL-adults mate and produce post-free-living (PFL) larvae that are exclusively female and now definitively committed to become infective L3i larvae.

In addition to the conditions that produce L3i outside of the host, *S. stercoralis* has the ability to remain in the host and undergo continuous autoinfection (Figure 1). This is due to the presence of L1 larvae that develop directly into autoinfective third-stage larvae (L3a) within the intestine. Similar to their L3i counterparts, L3a infect the host, in this case by penetrating the intestinal wall and entering parenteral tissues as activated L3+ to complete the parasitic lifecycle. Autoinfection is unique to *S. stercoralis* and allows the parasite to persist in the host for decades as a latent, often asymptomatic infection. However, under certain host conditions such as immunosuppression by glucocorticoids, the autoinfection spirals out of control, dramatically increasing the parasite burden. The resulting hyperinfection leads to a breakdown of the intestinal mucosal barrier and dissemination of invasive larvae throughout the body accompanied by bacterial infection leading to sepsis that is responsible for the high mortality. The current treatment of choice is the nematode-selective chloride channel activator ivermectin, which is effective at controlling acute infections, but is limited by its inability to eradicate the persistent autoinfective larvae (Krolewiecki et al., 2013; Repetto et al., 2018). Perhaps for this reason, the efficacy of ivermectin in preventing fatality due to the hyperinfection and disseminated forms of the disease is as low as 50% (Buonfrate et al., 2013), and cases of ivermectin resistance are now being reported in other nematode parasites (Prichard, 2007). The current increased prevalence of strongyloidiasis has stimulated efforts to include increased dosing of ivermectin through mass drug administration (Bisoffi et al., 2013), which in the long-term could accelerate ivermectin resistance in *S. stercoralis*. Of further immediate concern, the risk of hyperinfection has risen dramatically with the use of glucocorticoids to treat inflammatory diseases, particularly SARS-CoV-2 (Moloo, 2020). For

these reasons, there is an urgent need to develop new therapeutic strategies for treating strongyloidiasis (Krolewiecki et al., 2013; Moloo, 2020).

The lifecycle of *S. stercoralis* has similarities to the free-living nematode, *C. elegans*. The developmentally arrested L3i stage of *S. stercoralis* is analogous to the L3 dauer (d) stage of *C. elegans*. In *C. elegans*, L3d development is governed by DAF-12 (Antebi et al., 1998; Antebi et al., 2000), a nematode-specific nuclear receptor that is conserved in parasitic species (Ayoade et al., 2020; Long et al., 2020; Ma et al., 2019; Motola et al., 2006; Ogawa et al., 2009; Wang et al., 2017; Wang et al., 2009). In favorable environments, developing larvae synthesize the endogenous *C. elegans* (*Ce*)-DAF-12 ligands called dafachronic acids (Mahanti et al., 2014; Motola et al., 2006). The most potent and abundant of these ligands is Δ^7 -dafachronic acid (Δ^7 -DA), which induces a transcriptional program that governs metabolism and reproductive growth to mature adults (Bethke et al., 2009; Hammell et al., 2009; Wang et al., 2015). The final and rate-limiting step of Δ^7 -DA synthesis is catalyzed by DAF-9, a cytochrome P450 (Gerisch & Antebi, 2004; Jia et al., 2002; Motola et al., 2006). In unfavorable environments, Δ^7 -DA is not produced and unliganded *Ce*-DAF-12 functions as a transcriptional repressor that arrests growth as L3d larvae in a process known as dauer diapause. When favorable conditions return, Δ^7 -DA synthesis resumes, DAF-12 is transcriptionally active, and worms exit L3 dauer and continue reproductive development. Our previous work demonstrated a similar requirement for the orthologous *S. stercoralis* (*Ss*)-DAF-12 receptor in governing L3i (Albarqi et al., 2016; Wang et al., 2009). Although the endogenous *Ss*-DAF-12 ligand was unknown, we demonstrated that pharmacologic administration of Δ^7 -DA to PP-L1 or PFL-L1 larvae commits them to free-living reproductive development, even under conditions that would normally commit them to become L3i (Albarqi et al., 2016; Wang et al., 2009), and institutes a transcriptomic profile in L3i similar to L3+ (Stoltzfus

et al., 2014). In addition, knockout of *Ss*-DAF-12 prevents the formation of L3i larvae (Cheong et al., 2021), and in a mouse model of hyperinfection, exogenous $\Delta 7$ -DA treatment lowers the worm burden in the intestine (Patton et al., 2018).

Despite these findings, an understanding of the DAF-12 signaling pathway during parasitism and importantly whether targeting the *Ss*-DAF-12 receptor is a viable, curative strategy for treating strongyloidiasis is lacking. In this report, we identified the endogenous *Ss*-DAF-12 ligand, characterized its biosynthetic pathway, and demonstrated how its regulation governs the parasite's lifecycle. Finally, using a relevant pre-clinical animal model, we show that pharmacological activation of *Ss*-DAF-12 overcomes the deficiencies of ivermectin, and that when used in combination with ivermectin, provides a combinatorial therapeutic response that may be curative.

RESULTS

$\Delta 7$ -DA is the endogenous ligand for DAF-12 in *S. stercoralis*

Our previous work had demonstrated $\Delta 7$ -DA is able to bind and activate *Ss*-DAF-12 (Wang et al., 2009). However, whether $\Delta 7$ -DA or a related molecule is the endogenous *S. stercoralis* ligand is unknown. Indeed, the finding that the ligand binding pocket of *Ss*-DAF12 is divergent from that of *Ce*-DAF-12 (Wang et al., 2009) and the observation that *S. stercoralis* lacks an obvious ortholog of DAF-9 (the only known DA-synthesizing enzyme found in *C. elegans*) suggested that the *Ss*-DAF-12 ligand would likewise be divergent. To determine the identity of *S. stercoralis* DAF-12 ligands, we employed an unbiased, activity-based biochemical purification strategy (Figure 2-figure supplement 1). In a control experiment using a DA-deficient strain of *C.*

C. elegans supplemented with a known quantity of DA, we demonstrated this strategy effectively recovered 70% of the ligand (Figure 2-figure supplement 1B). Following this strategy, we fractionated lipids extracted from the FL-L3 larvae of *S. stercoralis*, which are analogous to the L3 stage of *C. elegans* where DA levels are highest (Li et al., 2013; Motola et al., 2006). Among the 70 HPLC fractions, *Ss*-DAF-12 ligand activity was detected only in fraction 23 in a cell-based reporter assay and this activity was dose-dependent (Figure 2A). Remarkably, fraction 23 co-eluted with dafachronic acids (Figure 2-figure supplement 1B), suggesting that the ligand is a related molecule.

To test whether the identified ligand activity is a dafachronic acid, we utilized a method incorporating ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS) that specifically detects all known DA ligands (e.g., Δ 4-DA, Δ 7-DA, and Δ 1,7-DA). Surprisingly, comparing the UPLC-MS data to DA standards (Table 1) revealed the presence of Δ 7-DA (Figure 2B) but no other congeners, such as Δ 4-DA and Δ 1,7-DA (Figure 2-figure supplement 2). The predicted endogenous concentration of Δ 7-DA in *S. stercoralis* FL-L3 is ~200 nM, which is well above the concentration needed to fully activate *Ss*-DAF-12 (Figure 2B, inset). Taken together, these data demonstrate that Δ 7-DA is present in *S. stercoralis* and acts as an endogenous DAF-12 ligand.

Δ 7-DA levels correlate with reproductive development in *S. stercoralis* lifecycle

In *C. elegans*, DAF-12 ligands promote reproductive development (Bethke et al., 2009; Hammell et al., 2009; Motola et al., 2006) and adulthood longevity (Gerisch et al., 2007; Yamawaki et al., 2010). To examine where in the *S. stercoralis* lifecycle Δ 7-DA is present, lipid extracts from each developmental stage were analyzed by UPLC-MS (Figure 3). In the post-parasitic environment under conditions that promote free-living development, Δ 7-DA was present

in FL-L1/L2 and was significantly more abundant in the FL-L3 stage as the larvae progress toward reproductive maturity (Figure 3A-C). Similarly, $\Delta 7$ -DA was detected in L3+ that have just infected the host and begun their reproductive development (Figure 3A-C). These findings are consistent with what is observed in *C. elegans* undergoing normal reproductive development (Li et al., 2013; Motola et al., 2006). A unique aspect of *S. stercoralis* is that after one free-living generation outside of the host, PFL larvae are fated to growth arrest at L3i. In concordance with the hypothesis that developmental arrest is due to the absence of a DAF-12 ligand, $\Delta 7$ -DA was undetectable in FL-adults, PFL-L1, and L3i larvae (Figure 3A-C).

The intestinal (Int)-L1-L3a larvae that were the direct progeny of parasitic adults in hyperinfected gerbils also had virtually no $\Delta 7$ -DA (Figure 3A-C). These larvae that remain within the intestine are committed to become infectious as L3a, similar to their post-free living counterparts that become L3i (Lok, 2007; Viney & Lok, 2015). By comparison, in the external post-parasitic environment under temperature conditions that mimic the host intestine, the PP-L1 are also fated to become infectious as L3i (Figure 3C) (Albarqi et al., 2016). The absence of $\Delta 7$ -DA in these two stages (L3i and L3a) is similar to the developmental diapause observed in *C. elegans*, in which larvae arrest at the L3d stage in the absence of the DAF-12 ligand (Motola et al., 2006). Taken together, these results indicate that liganded DAF-12 in *S. stercoralis* is required for reproductive development, while unliganded DAF-12 is requisite for production of infectious L3i and L3a larvae.

Another intriguing finding was that the highest concentration of $\Delta 7$ -DA occurred in parasitic adults, as opposed to the essentially undetectable levels in free-living adults (Figure 3B). This difference in $\Delta 7$ -DA levels correlated with the markedly different lifespans of the two adult populations. Parasitic adults live for up to a year or more in the host, whereas free-living adults

survive for only a few days in soil (Lok, 2007; Viney & Lok, 2015). Given that $\Delta 7$ -DA is known to extend lifespan of adult *C. elegans* (Gerisch et al., 2007; Yamawaki et al., 2010), this finding suggests that $\Delta 7$ -DA may play a similar role in extending the lifespan of parasitic adults in *S. stercoralis*.

Identification of the $\Delta 7$ -DA biosynthetic pathway in *S. stercoralis*

In *C. elegans*, DAF-12 ligands are synthesized from dietary cholesterol by a cascade of enzymes including a Rieske oxygenase (DAF-36), a short-chain hydroxysteroid dehydrogenase (DHS-16), and a cytochrome P450 (CYP; DAF-9) that catalyzes the final and rate-limiting step in dafachronic acid synthesis (Figure 4A) (Motola et al., 2006; Rottiers et al., 2006; Wollam et al., 2012; Wollam et al., 2011). Bioinformatic analysis of the *S. stercoralis* genome revealed single homologs for both DAF-36 and DHS-16 (Stoltzfus et al., 2012), which share sequence identity with their *C. elegans* counterparts. In contrast, there are 26 CYPs in *S. stercoralis*, but none of these share predictive sequence identity with DAF-9 (~36% at the best) (Stoltzfus et al., 2012). The lack of an obvious DAF-9 ortholog suggested the possibility that $\Delta 7$ -DA might be acquired exogenously by *S. stercoralis*. To rule out this possibility, we first determined whether *S. stercoralis* synthesize $\Delta 7$ -DA from dietary cholesterol in vivo. Free-living PP-L1 were cultured on a diet where the natural cholesterol isotope (largely ^{12}C -cholesterol) was supplemented with ^{13}C -labeled cholesterol. After 24 hours, we detected significant levels of ^{13}C -labeled $\Delta 7$ -DA in the FL-L3 (Figure 4B). These results demonstrated that $\Delta 7$ -DA is generated from dietary cholesterol in *S. stercoralis* and that the parasite has all of the necessary enzymatic machinery to perform the synthesis.

To characterize the biosynthetic enzymes, we employed a Sf9 cell expression system that we used to identify the *C. elegans* counterparts of these proteins (Motola et al., 2006; Rottiers et

al., 2006; Wollam et al., 2012; Wollam et al., 2011). To avoid potential interference from any endogenous substrates in Sf9 cells, we utilized ^2H -isotope-labeled substrates to assay the activity of the candidate *S. stercoralis* orthologs, *Ss*-DAF-36 (SSTP_0000037900) and *Ss*-SCDH-16 (SSTP_0001031100, the homolog of *Ce*-DHS-16). Sf9 microsomes expressing *Ss*-DAF-36 readily converted cholesterol to 7-dehydrocholesterol (Figure 4C) with an efficacy comparable to the *C. elegans* enzyme (Figure 4D). Similarly, *Ss*-SCDH-16 catalyzed the conversion of lathosterol to lathosterone like *Ce*-DHS-16 (Figure 4E, F). These findings demonstrated that *S. stercoralis* has functional orthologs of DAF-36 and DHS-16.

The inability to predict the parasite's DAF-9 ortholog from our bioinformatic analysis prompted us to perform an unbiased screen to identify the enzyme from among all 26 *S. stercoralis* CYPs. Each of the 26 CYP enzymes was expressed in Sf9 cells (Figure 4-figure supplement 1) and assayed by UPLC-MS for their ability to synthesize Δ^7 -DA from lathosterone. Unambiguously, only one of the 26 CYPs, *Ss*-CYP22a9 (SSTP_0001032100) synthesized Δ^7 -DA at levels comparable to *Ce*-DAF-9 (Figure 4G). These results demonstrated that *Ss*-CYP22a9 is the DAF-9 isoenzyme in *S. stercoralis*.

Δ^7 -DA synthesis is required for reproductive development in *S. stercoralis*

In *C. elegans*, favorable environmental cues induce DAF-9 expression and DAF-12 ligand synthesis through a cGMP signaling pathway, leading to reproductive development (Hu, 2007). Likewise in *S. stercoralis*, favorable host conditions act through a similar pathway to stimulate feeding, a sign of reactivated development in L3i (Stoltzfus et al., 2014). To study the role of Δ^7 -DA synthesis in parasite reproductive development, we first asked whether Δ^7 -DA is made in response to activation of the cGMP pathway in L3i. To that end, we treated L3i with 8-Br-cGMP, which mimics the presence of the host environment by activating the cGMP signaling pathway,

and then tested endogenous $\Delta 7$ -DA levels in the L3i larvae. In the presence of 8-Br-cGMP, we found that endogenous $\Delta 7$ -DA was increased progressively over a 3-day period to levels (~100 nM) that would saturate *Ss*-DAF-12 occupancy (Figure 5A). Furthermore, this stimulation of $\Delta 7$ -DA synthesis correlated exactly with the expression of *Ss-cyp22a9* (Figure 5-figure supplement 1A) and was abolished by co-treatment with ketoconazole, a broad-spectrum CYP inhibitor (Figure 5A). These results highlight the importance of $\Delta 7$ -DA synthesis in the reactivation of L3i larval development.

We next tested the requirement of *Ss*-CYP22a9 for $\Delta 7$ -DA synthesis and parasite development in vivo. For these experiments, a CRISPR-mediated, homology-directed gene knockout strategy was used to insert a GFP expression cassette into the *Ss-cyp22a9* gene locus through homologous repair (Figure 5-figure supplement 1B, C). This strategy allowed us to enrich for *Ss-cyp22a9* knockout worms by selecting GFP-positive L3i. Single worm genotyping confirmed the presence of at least one disrupted *Ss-cyp22a9* allele in >60% of the GFP-positive L3i (Figure 5B). To evaluate the phenotype due to loss of *Ss*-CYP22a9, we assayed cGMP-induced feeding behavior in L3i, which as noted above is an early marker of the transition to reproductive development (Lok, 2007; Stoltzfus et al., 2014; Viney & Lok, 2015). In both wildtype larvae and CRISPR-control larvae in which a gene unrelated to development (*Ss_unc-22*) was targeted, 8-Br-cGMP strongly induced the feeding behavior as expected (Figure 5C). In contrast, in *Ss-cyp22a9* knockout larvae, cGMP-induced feeding behavior was severely impaired (Figure 5C). The residual cGMP-induced response is likely due to the presence of an incomplete penetrance of the knockout in all worms. The loss of this feeding behavior in *Ss-cyp22a9*-deficient larvae was rescued completely by treatment with exogenous $\Delta 7$ -DA, further demonstrating the importance of DAF-12 activation as a requirement for parasite development (Figure 5C). To confirm the enzymatic

function of *Ss*-CYP22a9, we also analyzed the production of Δ 7-DA in *Ss-cyp22a9* knockout L3i larvae. For this experiment, we targeted the *Ss-cyp22a9* gene using non-homologous end joining CRISPR with the same sgRNA as in Figure 5C and Figure 5-figure supplement 1C. This CRISPR method permitted the generation of larger numbers of *Ss-cyp22a9* knockouts, which were necessary to detect endogenous Δ 7-DA levels. Consistent with the results of the CYP inhibitor, disrupting the *Ss-cyp22a9* gene abolished the Δ 7-DA induction by cGMP (Figure 5D). Taken together, these results demonstrated the crucial role of *Ss*-CYP22a9 in Δ 7-DA synthesis and highlight the importance of Δ 7-DA synthesis in the development of infectious larvae in *S. stercoralis*.

Δ 7-DA suppresses parasitic burden in uncomplicated strongyloidiasis

In *S. stercoralis*, uncomplicated infections are frequently asymptomatic but can last for years due to the persistence of L3a worms that escape the host immune system and continually re-infect the host at a low level. However, when the host is immune suppressed and the intestinal barrier is compromised, autoinfection accelerates out of control as more and more L3a worms invade the host, leading to a lethal hyperinfection. The results above suggested that targeting the DAF-12 pathway might provide a novel therapeutic opportunity for treating this disease. This strategy is based on the idea that like their L3i counterparts in the environment, the lack of Δ 7-DA is required for intestinal larvae to become infectious L3a (Figure 3C). Thus, we postulated that pharmacological activation of DAF-12 in intestinal larvae should block autoinfection by preventing the formation of filariform L3a larvae as it does with L3i in the environment (Albarqi et al., 2016; Wang et al., 2009). We first asked whether Δ 7-DA can successfully treat the uncomplicated, latent form of the disease. To that end, we employed a well-established gerbil

model that mimics both uncomplicated and hyperinfective strongyloidiasis found in humans (Kerlin et al., 1995; Nolan et al., 1993).

For the uncomplicated model, we infected gerbils with 1000 L3i and after 21 days began administering vehicle or $\Delta 7$ -DA orally in their drinking water, which delivers the compound directly into the gut where the intestinal larvae reside. We then monitored the parasite burden of the intestine by counting the number of fecal larvae. Compared to vehicle, treatment with $\Delta 7$ -DA for 14 days dramatically reduced fecal larval output by ~90% (312 ± 103 larvae per gram feces for vehicle versus 32 ± 6 for DA, $q < 0.03$; Figure 6A). In contrast, the numbers of parasitic adults, which produce intestinal larvae, were not significantly changed by $\Delta 7$ -DA treatment (Figure 6B). Because of the time-frame of this experiment and the fact that autoinfection is minimal in the uncomplicated model (Nolan et al., 1993), reinfection of the host by L3a larvae is negligible, demonstrating that these adult parasites were derived from the L3i of the initial infection. This explains why the numbers of adults (in contrast to the intestinal larvae) were not substantially reduced by $\Delta 7$ -DA treatment. These results are also consistent with our observation that intestinal larvae lack $\Delta 7$ -DA (Figure 3), which is essential for L3a development, thereby supporting the hypothesis that $\Delta 7$ -DA specifically targets the intestinal larval stages of the lifecycle. We conclude that $\Delta 7$ -DA treatment impedes the development of intestinal larvae and thus blocks transmission in uncomplicated infections where conventional treatments are only partially effective.

$\Delta 7$ -DA improves survival of a lethal strongyloidiasis hyperinfection

Based on the finding that $\Delta 7$ -DA disrupts intestinal larval development (Figure 6A), we next asked whether the DAF-12 ligand would be effective at treating the lethal form of strongyloidiasis. For this experiment, beginning at the time of infection with L3i, gerbils were administered the glucocorticoid, methylprednisolone, on a weekly basis (Nolan et al., 1993).

Similar to what is observed in immunocompromised humans, this results in the rapid progression of disease to a disseminated hyperinfection that is lethal to all of the animals, with >90% of them dying within 40 days (Figure 7A, black line). In contrast, when a matched group of these animals was treated with $\Delta 7$ -DA starting at 10 days after the hyperinfection was initiated, there was an impressive 70% survival rate that lasted for at least 90 days at which point we arbitrarily terminated the experiment (Figure 7A, blue line). Autopsies of these animals showed that hyperinfection resulted in a massive increase in the number of viable intestinal parasites ($>10^4$) in vehicle treated gerbils, which was reduced substantially in $\Delta 7$ -DA treated animals (Figure 7B-D). Notably, the number of autoinfected L3+ larvae in parenteral tissues, which drive the resulting pathogenesis, was reduced by 90% (and in some cases was undetectable) in $\Delta 7$ -DA treated animals compared to vehicle treated animals (Figure 7C). These results are consistent with what was observed in the uncomplicated infection and supports the conclusion that $\Delta 7$ -DA treatment impedes the development of L3a. Compared to vehicle-treated gerbils with uncomplicated infections (Figure 6B), we observed a >10-fold increase in adult parasites in hyperinfected vehicle-treated gerbils (Figure 7D). However, unlike in the uncomplicated infection, there was a significant decrease in adult parasites in the $\Delta 7$ -DA-treated gerbils that had a hyperinfection (50% vs the vehicle treated, Figure 7D). This difference is because in a hyperinfection the parasitic adults are largely derived from the expanding L3a population, whereas in an uncomplicated infection the number of adults that were present matured directly from the L3i larvae used for the initial infection. Overall, these findings demonstrated that $\Delta 7$ -DA treatment is effective in treating a lethal *S. stercoralis* hyperinfection.

$\Delta 7$ -DA and ivermectin act cooperatively to treat strongyloidiasis hyperinfection

As the current front-line drug for treating strongyloidiasis, ivermectin is effective at removing adult *S. stercoralis* parasites (Krolewiecki et al., 2013; Repetto et al., 2018). However, in hyperinfected patients ivermectin treatment is only 50-60% effective at preventing death (Buonfrate et al., 2013). This high mortality is due to the relatively low efficacy of ivermectin at killing the persistent autoinfective L3a larvae. Given that $\Delta 7$ -DA specifically targets the L3a population, we hypothesized that the combination of $\Delta 7$ -DA and ivermectin would act cooperatively to treat a strongyloidiasis hyperinfection. To test this, we first established an ivermectin treatment model in hyperinfected gerbils that mimics the efficacy observed in humans (Figure 7-figure supplement 1). In this model, 300 $\mu\text{g/kg}$ ivermectin delivered i.p. acutely cleared fecal larva output in $\sim 40\%$ of the hyperinfected gerbils within 7 days, resulting in $\sim 25\%$ survival rate for at least 90 days (Figure 7A, red line). As expected, ivermectin was as effective as $\Delta 7$ -DA in removing adult parasites from animals undergoing hyperinfection (Figure 7D), but in contrast to $\Delta 7$ -DA, ivermectin was ineffective at decreasing either the intestinal or L3+ larval populations (Figure 7B, C). Next, we treated hyperinfected gerbils with both $\Delta 7$ -DA and ivermectin. We found that the combination of both agents improved the survival rate significantly over either agent alone ($>75\%$, Figure 7A) and reduced the parasite burden of all life stages (Figure 7B-D). Remarkably, the combination of $\Delta 7$ -DA and ivermectin completely eliminated the parasites from all the animals that survived, essentially curing them of the disease (Figure 7E). In contrast, when treated with ivermectin or $\Delta 7$ -DA alone, $\leq 10\%$ were parasite-free even among those animals that survived (Figure 7E). Taken together, these results demonstrated that $\Delta 7$ -DA and ivermectin act synergistically in successfully eliminating *S. stercoralis* by targeting complementary stages of the lifecycle (Figure 8).

DISCUSSION

The worldwide prevalence of *S. stercoralis* infections and the increased risk of deadly hyperinfection due to the broad use of glucocorticoids to treat inflammatory diseases underscores the urgent need for new therapeutic approaches to treat strongyloidiasis (Buonfrate et al., 2013; Repetto et al., 2018). The difficulty in treating the disease arises from a persistent autoinfection in which L3a are produced and continuously re-infect the host. Consequently, the parasite burden can become uncontrollably large when the immune system is compromised, leading to frequent lethality. Our previous studies have suggested one potential target of interest is the nuclear receptor, DAF-12 (Patton et al., 2018; Wang et al., 2017; Wang et al., 2009), which is required for the transition into and out of the L3i stage of the parasite's lifecycle (Cheong et al., 2021). Here, we addressed two key unanswered questions: what is the nature and role of the *Ss*-DAF-12 ligand, and is targeting the *Ss*-DAF-12 pathway a viable therapeutic strategy? In this report, we identified $\Delta 7$ -DA as the endogenous ligand of *Ss*-DAF-12 and showed that the regulation of its biosynthesis is a requirement for both reproductive growth and the development of infectious stage larvae. Similar to the free-living nematode, *C. elegans*, we found the presence of $\Delta 7$ -DA is a requisite feature for *S. stercoralis* free-living and parasitic larvae to mature into reproductive adults. In contrast, we discovered $\Delta 7$ -DA is absent during the formation of L3a. Thus, like the analogous development of L3i in the environment, unliganded DAF-12 appears to be required for L3a formation in hosts. Taken together, these findings revealed a vulnerability in the life cycle of *S. stercoralis* and suggested two new therapeutic strategies: either blocking the synthesis of the ligand to prevent reproductive development or precociously activating DAF-12 in the intestine to prevent autoinfection.

To that end, we showed that knocking out the $\Delta 7$ -DA biosynthetic enzyme prevents the initiation of reproductive development. Concomitantly, when gerbils infected with *S. stercoralis* were treated with $\Delta 7$ -DA, development of L3a was severely impaired, thereby suppressing the parasite's autoinfection cycle in both uncomplicated and hyperinfection forms of strongyloidiasis. Strikingly, when $\Delta 7$ -DA was combined with the front-line medication, ivermectin, there was a near complete remission of the hyperinfection that resulted in a substantial increase in survival (from 25% with ivermectin alone to 75% with the combination treatment). Notably, in all of the surviving animals receiving both $\Delta 7$ -DA and ivermectin, no parasites from any stage were detected anywhere in the body, suggesting that the co-treatment resulted in a complete cure.

Advantages of DAF-12 as a Therapeutic Target

The synergistic response of $\Delta 7$ -DA and ivermectin highlights the unique potential of targeting the DAF-12 signaling pathway and overcoming the limitations of using ivermectin alone. Mortality rates in ivermectin-treated patients with hyperinfection range as high as 50% (Buonfrate et al., 2013). As an inhibitor of muscular function, ivermectin is highly effective at killing adults and feeding larvae (Repetto et al., 2018), but less effective at killing the developmentally quiescent L3a larvae that continuously drive autoinfection. In contrast, $\Delta 7$ -DA directly interferes with infectious L3a larval development by binding to unliganded DAF-12 and provoking an inappropriate developmental response inside the host that results in death of the larvae. In this way, the two drugs complement each other by targeting different stages of the lifecycle (Figure 8). Targeting the ligand binding properties of DAF-12 has other distinct advantages in that this nuclear receptor is nematode-specific and mutants resistant to pharmacologic ligands are unlikely to develop, since such mutants would be expected to disrupt the endogenous function of the receptor and otherwise be lethal.

The Conundrum of $\Delta 7$ -DA as the *Ss*-DAF-12 Ligand

An intriguing aspect of this study was the finding that $\Delta 7$ -DA is the endogenous ligand for *Ss*-DAF12. Although $\Delta 7$ -DA was first identified as the endogenous DAF-12 ligand in *C. elegans*, its presence in *S. stercoralis* was unexpected. In comparison to its *C. elegans* homolog, the *Ss*-DAF-12 ligand binding domain shares only moderate sequence identity (42%) and exhibits a distinct pharmacologic profile in response to $\Delta 7$ -DA compared to other species (Wang et al., 2009). The sequences of other regulatory proteins in the *Ss*-DAF-12 pathway also have diverged. For example, the cytochrome P450 (*Ss*-CYP22a9) that catalyzes the synthesis of $\Delta 7$ -DA (Figure 4) and the ligand-dependent coactivator that *Ss*-DAF-12 requires for transactivation (*Ss*-DIP-1) (Cheong et al., 2021) are both unique to *Strongyloides spp.*

In spite of these differences, several lines of evidence indicate that $\Delta 7$ -DA is the major, if not exclusive, DAF-12 ligand in *S. stercoralis*. First, no other ligand activities, including other types of dafachronic acids were detected. Second, the endogenous concentration of $\Delta 7$ -DA in *S. stercoralis* (~200 nM) is sufficient to drive full activation of *Ss*-DAF-12, leaving other potential DAF-12 ligands redundant if they do exist. Finally, knocking out the *daf-9* homolog, *Ss-cyp22a9*, which is required to synthesize $\Delta 7$ -DA, prevents DAF-12-dependent activity in vivo, and that activity is rescued completely by adding back the ligand. Interestingly, $\Delta 7$ -DA has been shown to activate DAF-12 homologs in other species (Ayoade et al., 2020; Long et al., 2020; Ma et al., 2019; Ogawa et al., 2009; Wang et al., 2009). Why the $\Delta 7$ -DA hormone has been evolutionarily conserved, whereas other components of the pathway have not, remains unclear, but nevertheless highlights the importance of the ligand in governing nematode biology.

Therapeutic Potential Beyond *S. stercoralis*

The findings discussed above underscore the potential of developing agonists that would precociously activate unliganded *Ss*-DAF-12 and kill L3a larvae, a therapy that would be propitious and specific to *S. stercoralis*. However, the observation that liganded DAF-12 also is required at a completely different but essential stage of the lifecycle to promote reproductive growth raises the possibility of also targeting DAF-12 with an antagonist. Given that DAF-12 has been found in all nematode species surveyed to date (Ayoade et al., 2020; Long et al., 2020; Ma et al., 2019; Ogawa et al., 2009; Wang et al., 2009), antagonizing the receptor would be expected to prevent development of adult worms in all parasitic species, offering a unique, broad-spectrum approach for treating most, if not all, nematode parasitisms.

In addition to targeting the receptor, the identification of *Ss*-CYP22a9 as the Δ 7-DA synthesizing enzyme that is required for reproductive development reveals the potential of developing an enzyme inhibitor. Such an inhibitor would prevent synthesis of the endogenous ligand and thus the requisite activation of DAF-12 for reproductive growth. Indeed, the finding that the broad spectrum CYP-inhibitor, ketoconazole, was effective at blocking Δ 7-DA synthesis in the present study and was shown previously to block developmental activation of cultured L3i (Albarqi et al., 2016) supports this strategy.

While our study provides a proof of concept for the therapeutic use of an *Ss*-DAF-12 ligand, we note that Δ 7-DA may not be the best candidate for eventual clinical use. Typical of most endogenous steroid receptor ligands, Δ 7-DA has a short half-life and relatively poor pharmacokinetic properties in vivo (Patton et al., 2018). For this reason, in our study we administered Δ 7-DA continuously in the drinking water over many days. Although overcoming this limitation would be important for developing a suitable therapeutic modality, this is not an unrealistic goal. Encouragingly, in the case of all other nuclear receptors this limitation has been

circumvented through the design of potent, long-lasting receptor agonists and antagonists (Chen, 2008; Zhao et al., 2019). Another limitation of this study is that we only tested single doses of $\Delta 7$ -DA and ivermectin. However, we note that optimizing the dose regimens are likely to reveal even greater cooperative effects. Finally, we have not definitively ruled out the existence of other endogenous DAF-12 ligands. While the findings that $\Delta 7$ -DA is the only ligand we detected and is present only at the times when DAF-12 would be expected to be an activator are consistent with the conclusion that $\Delta 7$ -DA is the relevant ligand, it is feasible that other activities exist that were not identified in our purification scheme.

Conclusions

In summary, in this work we identified the endogenous DAF-12 ligand in the human parasitic nematode *S. stercoralis*, characterized the ligand's biosynthesis pathway, and demonstrated that activating DAF-12 can overcome the limitation of the front-line drug, ivermectin, and significantly improve the outcome of strongyloidiasis in a preclinical model of hyperinfection. Our study further revealed the ligand's biosynthetic enzyme as a potential new target that might also be exploited to treat this lethal parasitic disease.

FIGURES

Figure 1. Life cycle of *S. stercoralis*.

Life cycle of *S. stercoralis*. Similar to other nematodes, *S. stercoralis* hatch from eggs and undergo four larval (L) molts to become adults. However, under certain conditions, the larvae arrest their development as infectious third-stage larvae. The parasite has two infectious stages (highlighted in yellow), one that exists in the environment as L3i and one that exists in the mucosa of the host intestine as an autoinfective L3a.

Figure 2. Identification of $\Delta 7$ -dafachronic acid as the endogenous DAF-12 ligand in *S. stercoralis*.

(A) Purification of the endogenous *S. stercoralis* ligand for Ss-DAF-12. Lipids from post-parasitic L3 worms were extracted and fractionated as described in Figure 2-figure supplement 1. The resulting lipid fractions were then tested in a Ss-DAF-12 cell-based reporter assay. Inset: Dose response of the endogenous activity in fraction 23. RLU, relative luciferase units. Data are presented as the mean $\pm$ s.d. of technical triplicates.

(B) $\Delta 7$ -DA is specifically present in the active lipid fraction. HPLC fractions 21–25 were analyzed by UPLC-MS. CDCA- 2 H $_4$ (100 nM) was added to each fraction as an internal standard and has a retention time (Rt) of 0.5 min (arrow). Inset: Dose response of $\Delta 7$ -DA in the Ss-DAF-12 reporter assay. Data are presented as the mean $\pm$ s.d. of technical triplicates and were repeated 3 times.

See also Figure 2-figure supplement 1 and 2.

Figure 3. Profiling of $\Delta 7$ -DA in developmental stages of *S. stercoralis*.

(A) Detection of $\Delta 7$ -DA during the lifecycle of *S. stercoralis*. Lipid extracts from the indicated stages of *S. stercoralis* were analyzed by derivatizing $\Delta 7$ -DA to $\Delta 7$ -DA-picolylamine, which then was detected by UPLC-MS in positive MRM mode with m/z transition $505 \rightarrow 487$. Parasitic stages were recovered from hyperinfected gerbils. Arrowheads show $\Delta 7$ -DA peaks. Note that in the extracts from L3+ larvae, the peak with the faster retention time (1.95 min) is an unknown metabolite that is only found at this stage.

(B) $\Delta 7$ -DA levels were determined in the stages shown in (A) by comparison to a known standard. $n = 3 \pm \text{s.d.}$; *, $p < 0.03$ by student t-test compared to L3i larvae.

466 (C) Schematic summary of $\Delta 7$ -DA levels in the development stages of *S. stercoralis*. $\Delta 7$ -DA is
467 absent in larvae developing to infectious stages (i.e., L3i and L3a) and is present in larvae
468 undergoing reproductive development.

469

Figure 4. Characterization of the Δ7-DA biosynthetic pathway in *S. stercoralis*.

(A) Diagram of Δ7-DA biosynthetic pathway in *C. elegans*. In blue are the known *C. elegans* enzymes followed in parentheses by the number of candidate orthologs found in *S. stercoralis*.

(B) Δ7-DA is synthesized de novo in *S. stercoralis*. Extracts from post-parasitic L1 worms cultured in the presence or absence of [13C]-cholesterol were assayed by UPLC-MS for incorporation of [13C] into Δ7-DA.

(C-D) *Ss*-DAF-36 catalyzes the synthesis of 7-dehydrocholesterol in the first step of Δ 7-DA biosynthesis. Sf9 microsomes expressing *Ss*-DAF-36 were incubated with vehicle or 100 μ M [2 H]-cholesterol and assayed for the synthesis of [2 H]-7-dehydrocholesterol by UPLC-MS chromatography (C), and the amount quantitated relative to that produced by the *C. elegans* ortholog, *Ce*-DAF-36 (D).

(E-F) *Ss*-SCDH-16 catalyzes the of synthesis of lathosterone in the penultimate step of Δ 7-DA biosynthesis. Sf9 microsomes expressing *Ss*-SCDH-16 were incubated with vehicle or 100 μ M [2 H]-lathosterol and assayed for the synthesis of [2 H]-lathosterone by UPLC-MS chromatography (E), and the amount quantitated relative to that produced by the *C. elegans* ortholog, *Ce*-DHS-16 (F).

(G) *Ss*-CYP22a9 catalyzes the synthesis of Δ 7-DA from lathosterone. Sf9 cells expressing one of each of the 26 *S. stercoralis* cytochrome P450 homologs were incubated with vehicle or 10 μ M lathosterone and assayed for the production of Δ 7-DA by UPLC-MS as in Figure 2. *Ce*-DAF-9 is shown as a positive control. Inset, chromatogram from the reaction with *Ss*-CYP22a9.

n = 3 $\pm$ s.d.; *, p < 0.03 by student t-test compared to vehicle.

See also Figure 4-figure supplement 1.

Figure 5. *Ss*-CYP22a9 is required for L3i activation and Δ 7-DA synthesis in *S. stercoralis*.

(A) Inhibition of cytochrome P450 activity blocks Δ 7-DA synthesis in parasites. L3i (100 worms/group) were treated with 0.5 mM 8-Br-cGMP in the presence or absence of 25 mM ketoconazole (Kcz). $n = 3 \pm \text{s.d.}$; $p < 0.03$ by t-test compared to vehicle (*) or 3d treatment with 8-Br-cGMP (#).

(B-C) *Ss*-CYP22a9 is required for cGMP-induced L3i activation. The *Ss-cyp22a9* gene was disrupted by CRISPR/Cas9-mediated, homology-directed repair as shown in Figure 5-figure supplement 1C. The resulting F1 generation of L3i worms expressing the positive selection marker (GFP) were sorted manually, subjected to single worm genotyping (B) and assayed for feeding behavior (C). Disruption of the *Ss-unc-22* gene was used as a control. *, $p < 0.03$ by Fisher's exact test ($n = 40$ -200 from three independent experiments).

(D) Δ 7-DA synthesis is abolished in *Ss-cyp22a9* knockout parasites. *Ss-cyp22a9* or *Ss-unc-22* (as a control) genes were disrupted by CRISPR using the same sgRNA plasmids in (B-C) and F1 generation L3i worms were assayed for Δ 7-DA levels as in Figure 3 after treatment with 0.5 mM

507 8-Br-cGMP. $n = 3 \pm \text{s.d.}$; *, $p < 0.03$ by t-test compared to wild type (WT) or *Ss-unc-22* worms
 508 treated with 8-Br-cGMP.

509 See also Figure 5-figure supplement 1.

510

Figure 6. Δ7-DA suppresses output of fecal larvae in latent, uncomplicated strongyloidiasis.

(A) Δ7-DA treatment reduces fecal larvae by >90% in gerbils infected with *S. stercoralis*.

(B) Adult parasite burden in infected gerbils measured at 14 days post-treatment.

n = 5 ± s.e.; *, q < 0.03 by Mann–Whitney U test compared to vehicle. n.s., not significant.

Figure 7. $\Delta 7$ -DA and ivermectin act cooperatively to treat disseminated strongyloidiasis hyperinfection.

(A) Kaplan-Meier survival curves of hyperinfected gerbils treated with vehicle (Veh), $\Delta 7$ -DA, and/or ivermectin (IVM). Sample sizes: $n = 18$ (Veh), 10 (DA), 10 (IVM), 9 (DA+IVM); $q < 0.03$, by log-ranked test compared to treatment with vehicle (*) or ivermectin alone (#).

(B-D) Parasite burden at various lifecycle stages from the hyperinfected gerbil treatment groups shown in (A). At the time of death, live intestinal L1-L3a (B), L3+ (C), and adult (D) parasites were counted. Sample sizes: $n = 15$ (Veh), 10 (DA), 10 (IVM), 9 (DA+IVM); $q < 0.03$, by Mann-Whitney U test compared to treatment with vehicle (*) or ivermectin alone (#).

(E) Co-treatment with $\Delta 7$ -DA and ivermectin eradicates parasites in hyperinfected gerbils. Animals from (A) with no detectable parasites in any part of the body after 70 days of treatment were scored as parasite-free. Notably, all the animals in the co-treatment group that survived hyperinfection (shown in (A)) were found to be parasite-free. Sample sizes: $n = 10$ (DA), 10 (IVM),

529 9 (DA+IVM); $q < 0.03$, by Fisher's exact test compared to treatment with vehicle (*) or ivermectin
 530 alone (#). DA, 50 μ M Δ^7 -DA administered in drinking water; IVM, 300 μ g/kg ivermectin by i.p.
 531 injection.
 532 See also Figure 7-figure supplement 1.
 533

Figure 8. Strategy for using DAF-12-based therapeutics to treat strongyloidiasis.

Administration of DAF-12 ligands like $\Delta 7$ -DA disrupt the lifecycle of nematode parasites by preventing the development of the infective L3i and L3a worms, where DAF-12 is normally unliganded. Pharmacologic activation of DAF-12 with $\Delta 7$ -DA prevents both environmental infection and autoinfection, which are essential features of the latent and hyperinfection forms of strongyloidiasis. In contrast, ivermectin kills only the actively developing stages and therefore is unable to target developmentally-quiescent infective L3i and L3a larvae. For this reason, the combination of the DAF-12 ligand and ivermectin achieves a synergistic, double blockade of the lifecycle.

544 SUPPLEMENTAL FIGURES

545 **Figure 2-figure supplement 1. Strategy for activity-based, DAF-12 ligand purification in *S.***
546 ***stercoralis*.**

547 (A) DAF-12 ligand purification scheme. (B) Determination of purification efficacy. To estimate
548 the efficiency of DA purification, 10 mM of Δ^4 -DA was added as a standard to ~2 million *C.*
549 *elegans daf9daf12* worms, a mutant strain that lacks endogenous DA. Following extraction, the
550 lipid fraction was further purified by HPLC. The amount of Δ^4 -DA in each of the 70 collected
551 HPLC fractions was analyzed by LC/MS in negative SIM mode at m/z 413. Shown are the only
552 fractions containing detectable Δ^4 -DA. Up to 70% of the Δ^4 -DA was recovered, the majority of
553 which was in Fraction 23. The experiment was repeated twice.

554

Figure 2-figure supplement 2. $\Delta 4$ -DA and $\Delta 1,7$ -DA are not present in infective L3 parasites.

(A) $\Delta 1,7$ -DA is undetectable in L3 parasites. The active DAF-12 fractions shown in Figure 2 were analyzed by UPLC-MS in negative SIM mode at m/z 411 and compared to the $\Delta 1,7$ -DA standard. $\Delta 1,7$ -DA has a distinct molecular mass that permits it to be separated from other DA congeners with this method. If $\Delta 1,7$ -DA was present, it would have been detected in Fraction 23. (B) $\Delta 4$ -DA is undetectable L3 parasites. $\Delta 4$ -DA and $\Delta 7$ -DA standards were separated and detected by UPLC-MS in negative SIM mode at m/z 413. Although $\Delta 4$ -DA has the same molecular mass as $\Delta 7$ -DA, the two compounds can be completely separated by retention times. Notably, the retention time of the peak in the active fraction shown in Figure 2 only matches $\Delta 7$ -DA.

Figure 4-figure supplement 1. Expression of the 26 *S. stercoralis* cytochrome P450 enzymes in insect Sf9 cells.

P450 enzymes were fused to C-terminal HA tags and detected by immunoblot using an anti-HA antibody. The *C. elegans* DAF-9 enzyme is shown as a positive control. The experiment was repeated 3 times.

Figure 5-figure supplement 1. In vivo characterization of the DAF-9 homolog (*Ss-CYP22a9*) in *S. stercoralis*.

(A) *Ss-cyp22a9* mRNA expression is increased by cGMP in L3i larvae. L3i larvae were treated as in Figure 5 and *Ss-cyp22a9* mRNA levels were measured by qPCR and compared to 18S rRNA levels. Results expressed as means $\pm$ S.D. from technical triplicates. *, $p < 0.01$ by t-test. Duplicate experiments were performed with similar results.

(B) CRISPR knockout strategy for targeting *Ss-cyp22a9* in *S. stercoralis*: Free-living adult females were microinjected with CRISPR targeting vectors (for either NHEJ or HDR gene editing) and allowed to mate. F1 progeny were grown to the L3i stage and GFP-positive worms were phenotyped and genotyped.

(C) Homology-directed repair targeting vector for *Ss-cyp22a9* CRISPR. Red line indicates position of the insertion repair template in the P450 domain of the *Ss-cyp22a9* gene (SSTP_0001032100). The guide sequence and PAM site (underlined) are shown. The recombinant locus expresses a

582 GFP marker from the *Sr-eef-1* promoter fused to the 3'-UTR of the *Ss-era-1* gene. F, R, forward
583 and reverse primers, respectively; HA, homology arms. WT and recombinant alleles produce 1052
584 bp and 823 bp products with F1/R1 and F1/R2, respectively.

Figure 7-figure supplement 1. Ivermectin mimics the treatment of a human *S. stercoralis* hyperinfection in gerbil models.

Vehicle or ivermectin (300 mg/kg) was injected i.p. into *S. stercoralis* hyperinfected gerbils at 21 days post-infection and fecal larval output was measured 7 days later. Ivermectin (IVM) treatment results in ~40% decrease in fecal larval output, but does not permanently eliminate parasites. n = 4 for vehicle, 10 for IVM treatment groups. *, $q < 0.03$ comparing to the day 21 data, by Mann-Whitney Wilcoxon test corrected with fdr method. Error bars represent the median +/- interquartile.

TABLES

Table 1. Detection methods for the compounds in this study.

Steroids	Retention time (min)	MS detection mode	Parent ion (m/z)	Product ion (m/z)
Δ^7 -DA	2.1	Negative SIM	413	N/A
Δ^4 -DA	1.9	Negative SIM	413	N/A
$\Delta^{1,7}$ -DA	2.0	Negative SIM	411	N/A
Δ^7 -DA-PA	2.1	Positive MRM	505	487
[^{13}C]- Δ^7 -DA-PA	2.1	Positive MRM	508	490
[^2H]-7-dehydrocholesterol	3.9	Positive MRM	374	109
[^2H]-lathosterone	4.1	Positive MRM	392	109

Table 2. Sample preparation for Δ^7 -DA quantification in *S. stercoralis*.

Parasite sample	Amount	Lysis method	Standard preparation
FL-L1/L2	200,000	Sonication	100 nM Δ^7 -DA compound spiked in 200,000 FL-L1/L2
FL-L3	50,000	Sonication	100 nM Δ^7 -DA compound spiked in 50,000 FL-L3
FL-adult	5,000	Sonication	100 nM Δ^7 -DA compound spiked in 5,000 FL-adults
PFL-L1	200,000	Sonication	100 nM Δ^7 -DA compound spiked in 200,000 PFL-L1
L3i	50,000	Sonication	100 nM Δ^7 -DA compound spiked in 50,000 L3i
L3+	1,000	Proteinase K	100 nM Δ^7 -DA compound spiked in 1,000 L3+
P-adult	500	Proteinase K	100 nM Δ^7 -DA compound spiked in 500 FL-adults
Intestinal L1-L3a	5,000	Proteinase K	100 nM Δ^7 -DA compound spiked in 5,000 Int-larvae
cGMP treated L3i	1,000	Proteinase K	100 nM Δ^7 -DA compound spiked in 1,000 L3i

Table 3. Oligo sequences used in this study.

	Sequence	Description
forward	GGCATCACCATACAAAACAG	<i>Ss-cyp22a9</i> wild type allele genotyping
reverse	TTTGTATGAGGAGGGTTGTG	
forward	GGCATCACCATACAAAACAG	<i>Ss-cyp22a9</i> KO allele genotyping
reverse	CATCACATTTCATCAAAAGTCCACT	
forward	TCCTGGCCAGTGCTAATGTTATT	<i>Ss-cyp22a9</i> qPCR
reverse	CTATTTGGACGGGATGAGAAGACT	
forward	TGGTGCATGGCCGTTCTTA	<i>Ss-18SRNA</i> qPCR
reverse	CTCGCTCGTTATCGGAATCAA	
forward	GCTGGGGACTTATGGACAGGgttttagagctagaaatagcaag	sgRNA expression plasmid
reverse	/5phos/CATTGTATTGGATGGCAATC	targeting <i>Ss-cyp22a9</i>

MATERIALS AND METHODS

Animal husbandry

All animal experiments were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee (IACUC) and are listed under animal protocol numbers 2016-101500 and 2018-102369. All protocols, as well as routine husbandry care of the animals, were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (National Research Council, 2011). Male dogs of 6~18 months were purchased from Oak Hill Genetics (Ewing, IL) and infected with 3000 L3i of *S. stercoralis* and were orally administrated 0.25~1.2 mg/kg prednisolone daily to maintain parasite production in feces. Male Mongolian gerbils (TUM/MON strain) of 6~9 weeks were purchased from Charles Rivers (Wilmington, MA) and used as described below.

Reagents

Dafachronic acids were synthesized as reported (Basu et al., 2015; Mahanti et al., 2014; Sharma et al., 2009). Methylprednisolone acetate (MPA) injection suspension (Zoetis, Parsippany, NJ), ketoconazole (Sigma, St. Louis, MO), 8-Br-cGMP (Tocris, Minneapolis, MN), ivermectin (Merial Limited, Duluth, GA) were purchased as cited. Solvents for lipid extraction and liquid chromatography (toluene, hexanes, isopropanol, methanol, water, and acetonitrile) were purchased from Fisher Scientific (Waltham, MA). Eluent additives for LC-MS (formic acid or NH₄Ac) were purchased from Sigma (St. Louis, MO).

S. stercoralis culture

The wild type (UPD strain) of *S. stercoralis* was maintained in purpose-bred dogs (Oak Hill Genetics, Ewing, IL) and free-living stages of *S. stercoralis* were prepared from coproculture of the dog feces as described (Lok, 2007). Briefly, post-parasitic worms at the noted stages were

obtained using the Baermann technique (Lok, 2007) from daily collected dog feces (for PP-L1/L2); 24 hr coproculture at 18°C (for FL-L3); 72 hr coproculture at 21°C (for FL-adults and PFL-L1); and 7-day coproculture at 25°C (for L3i). The parasitic stages of *S. stercoralis* were acquired from Mongolian gerbils (Charles Rivers, Wilmington, MA) as described (Lok, 2007; Stoltzfus et al., 2012). To obtain L3+, gerbils infected with 10,000 L3i larvae were sacrificed 3 days post infection. After removing the intestinal tract, parenteral tissues were minced and L3+ were collected by the Baermann technique at 37°C. To collect P-adults, intestinal L1-L3, and L3a, gerbils were hyperinfected by an initial inoculation of 4,000 L3i and administration of 2 mg MPA, followed by weekly injections of 2 mg MPA for 4 weeks. After sacrificing the gerbils, P-females and intestinal larval stages were collected by hanging the small and large intestines in cylinders filled with saline water supplemented with 0.5 mg/ml gentamicin (Sigma, St. Louis, MO) at 37°C, which allows the parasites to migrate out of the tissues and settle down at bottom of the cylinders. The parasites were then collected and purified by manually removing each stage under a dissection scope. Collected parasites were then washed 5 times with M9 buffer containing an antibiotic cocktail containing 100 units penicillin, 100 ug/ml streptomycin (ThermoFisher, Waltham, MA), and 50 µg/ml gentamicin (Sigma, St. Louis, MO) and stored in -80°C for lipid extraction.

Lipid fractionation and ligand identification

Endogenous DAF-12 ligands were purified from the lipid fractions of PP-L3 as outlined (Figure 2-figure supplement 1A). Briefly, ~5 million PP-L3s were obtained from ~100 kg dog feces as described above. The worms were pooled and sonicated in 0.9% NaCl, from which crude lipids were extracted by the Folch method (Folch et al., 1957). The crude lipids were dissolved in toluene and 0.1% acetic acid and passed through a Sep-Pak Silica SPE columns (Waters, Milford, MA), followed by sequential elution with hexanes, 30% isopropanol in hexanes, and finally

methanol, all of which contains 0.1% acetic acids. The lipids in the 30% isopropanol fraction were then fractionated with semi-preparative high-performance liquid chromatography (HPLC) with a C18 column (Luna 5 μ m C18 100 Å, 250 x 10 mm, Phenomenex, Torrance, CA) at a flow rate of 3.5 ml/min. The mobile phases were water (A) and acetonitrile (B), both containing 0.1% formic acid. The following gradient was run for a total of 70 min: 0-15 min with 50~100% (B); 15~70 min with 100% (B). Eluted fractions were collected every minute and dried under nitrogen gas and dissolved in ethanol.

HPLC fractions containing endogenous *Ss*-DAF-12 ligands were first identified using a cell-based reporter assay (Wang et al., 2009). Briefly, COS-7 cells (ATCC, Manassas, VA) cultured in DMEM (ThermoFisher, Waltham, MA) supplemented with 10% FBS (Gemini Bio, West Sacramento, CA) were co-transfected with plasmids expressing the *S. stercoralis* DAF-12 ligand binding domain fused in frame with the DNA binding domain from *C. elegans* DAF-12 (pCMX-Ce*Ss*-DAF-12, to increase expression efficiency) (Wang et al., 2009), the *lit-1 kinase* DAF-12 reporter plasmid (pNL3.1-DAF-12RE-*lit1*, fused to Nanoluc luciferase) and the control reporter plasmid (pGL4.53, *pgk* promoter fused to firefly luciferase). The cells were split into 384 well plates and treated with 10 nM Δ 7-DA or the HPLC fractions. After 24 hr, Nanoluc and firefly luciferase activities were measured by Nano-Glo Dual-luciferase kits (Promega, Madison, WI) on a Victor V plate reader (Perkin Elmer, Waltham, MA). Relative luciferase units (RLU) were then calculated by normalizing the Nanoluc luciferase activity to the firefly luciferase activity.

To characterize the chemical identity of the *Ss*-DAF-12 ligand, isolated HPLC fractions were subjected to ultra-performance liquid chromatography tandem with mass spectrometry (UPLC-MS) using a Shimadzu LC instrument (Shimadzu Scientific Instruments, Inc., Columbia, MD) in tandem with a Sciex 6500 Triple Quad mass spectrometer (AB Sciex LLC, Framingham, MA).

The HPLC fractions were diluted in methanol containing 100 nM chenodeoxycholic acid- $^2\text{H}_4$ (d4-CDCA, Sigma, St. Louis, MO) as an internal control of retention times between different runs. The lipids were then loaded onto a C18 column (Kinetex 1.3 μm C18 100 Å, LC Column 50 x 2.1mm, Phenomenex, Torrance, CA) at a 0.4 ml/min flow rate. The mobile phase consisted of (A) water:acetonitrile (9:1) and (B) acetonitrile:water (99:1), both containing 2 mM NH_4Ac . The following gradient was run for a total of 8 min: 60~80% of (B) over 0~2 min; 80% (B) over 2~4 min; 80~99% (B) over 4~6 min; and 99% (B) over 6~8 min. Using negative selective ion monitoring (SIM) mode, Δ^4 -DA and Δ^7 -DA were analyzed at m/z 413 (retention time [RT] = 1.89 min) and m/z 413 (RT = 2.08 min), respectively; $\Delta^{1,7}$ -DA was analyzed at m/z 411 (RT = 1.95 min). The identity of the peaks were determined by comparing to standards that were run in parallel with the lipid fractions.

Quantitative analysis of Δ^7 -DA levels in *S. stercoralis*

S. stercoralis at different developmental stages were prepared as described above and sample preparation was summarized in Table 2. For the environmental post-parasitic stages (PP-L1, FL-L3, FL-adults, PFL-L1 and L3i), worms were lysed by sonication in 0.9% NaCl. For the host-derived parasitic stages (L3+, P-adult and intestinal L1-L3a) and cGMP-treated L3i, worms were lysed in digestion buffer (2 mM Tris HCl, Ph 8.0, 1 mg/ml Proteinase K and 0.25% SDS) at 55°C for 2 hrs. SDS was then precipitated and removed by adding a saturating amount of KCl followed by centrifugation at $10,000 \times g$ for 5 min. For quantification, 100 nM Δ^7 -DA was added as a standard to lipid fractions from stages that do not have endogenous Δ^7 -DA (listed in Table 1) and were processed in parallel with other samples. Lysates from parasite samples and standards were extracted by the Folch method and lipids were dried under nitrogen. Δ^7 -DA in the lipids was then derived to Δ^7 -DA-picolyamine (Δ^7 -DA-PA) for analysis by incubating the lipids with 3.3 mM of

triphenylphosphine, 3.3 mM 2,2'-dipyridyl disulfide, and 333 ng/ul 2-picolylamine at 60°C for 20 min (Li et al., 2013). The $\Delta 7$ -DA-PA was then analyzed by UPLC-MS. The UPLC method was same as described above and $\Delta 7$ -DA-PA compounds were detected in positive multiple reaction monitoring (MRM) mode with m/z transition 505→487. DA quantification was then performed with the software MultiQuant (AB Sciex LLC, Framingham, MA) by comparing $\Delta 7$ -DA-PA peak areas in the parasite samples with those of 100 nM $\Delta 7$ -DA standards.

Biosynthesis of $\Delta 7$ -DA from dietary cholesterol in *S. stercoralis*

PP-L1 stages of *S. stercoralis* were prepared from dog feces as described above and cultured on NGM plates modified for metabolic tracing of isotope-labeled cholesterol supplemented in the diet. Briefly, HB101 bacteria were cultured overnight in cholesterol-free medium (10 g/L ether-extracted peptone in DMEM) and prepared as 10× concentrates supplemented with 140 μM naturally labeled (i.e., ^{12}C) or $^{13}\text{C}_3$ (Cambridge Isotope Laboratories, Tewksbury, MA) labeled cholesterol. The bacteria concentrates were then spotted on cholesterol-free NGM plates (3% agarose in S-basal) to form bacterial lawns. Approximately 10,000 PP-L1 larvae were cultured on the plates at 18°C for 24 h and collected and analyzed as described above for $\Delta 7$ -DA-PA- $^{13}\text{C}_3$ levels by UPLC-MS in the positive MRM mode with m/z transition 508→490.

In vitro enzyme activity assays

Candidate enzyme genes (Stoltzfus et al., 2012) were cloned and each gene expressed in Sf9 cells (ATCC, Manassas, VA), which are cultured with Sf 900 III medium (Thermofisher, Waltham, MA). A human CYP450 oxidoreductase (hOR) was co-expressed to facilitate electron transport required for the enzyme activities (Motola et al., 2006). Enzyme coding sequences were tethered with a C-terminal HA tag in pFastBac Dual baculoviral vectors (Invitrogen, Waltham, MA) using Ph or p10 expression cassettes for hOR or other enzymes, respectively. Baculovirus was prepared

according to manufacturer's instructions followed by infection of Sf9 cells. For DAF-36 and DHS-16 homologs, the microsomes expressing the enzymes were purified from the infected Sf9 cells with a Microsome Isolation Kit (Abcam, Cambridge, MA). Microsomes were incubated with an NADPH regeneration system (Promega, Madison, WI) in presence or absence of 100 μ M substrate compounds at 37°C for 16 hrs. For CYP activities, infected Sf9 cells were incubated with 10 μ M substrate compound at 28°C for 24 hrs. The substrate compounds for DAF-36, DHS-16 and CYPs were cholesterol-²H₇, lathosterol-²H₇ (Avanti Polar Lipids, Inc., Alabaster, AL), and lathosterone (Steraloids, Inc., Newport, RI), respectively. Lipids were then extracted from microsomes (for DAF-36s and DHS-16s) or Sf9 cells (for CYPs) by the Folch method and loaded onto a C18 column (Kinetex 1.3 μ m C18 100 Å, LC Column 50 x 2.1mm, Phenomenex, Torrance, CA) at a 0.4 ml/min flow rate. The mobile phase consisted of (A) water:acetonitrile (9:1) and (B) acetonitrile:water (99:1), both containing 2 mM NH₄Ac. For measuring the activities of the DAF-36 and DHS-16 homologs, the following gradient was run for a total of 8 min: 80~99% (B) for 0~2 min; 99% (B) for 2~8 min. Enzyme products were detected in positive MRM mode with m/z transition 374→109 (7-dehydrocholesterol-²H₇) and 392→109 (lathosterone-²H₇). For CYP activities, Δ 7-DA was analyzed by the UPLC-MS methods described above.

L3i activation assay

Reactivation of L3i developmental arrest was assayed by monitoring feeding activity as described (Albarqi et al., 2016; Cheong et al., 2021). Briefly, L3i larvae prepared as described above were suspended in M9 buffer at 100 larvae/96 well. The larvae were treated with 0.5 mM 8-Br-cGMP (Torcis, Minneapolis, MN), 1 μ M Δ 7-DA and/or 25 μ M of ketoconazole (Sigma, St. Louis, MO) at 37°C for 22 hrs. To visualize the feeding behaviors, worms were incubated with 200 μ g/ml of Alexa 594 fluorescent dye (Thermofisher, Waltham, MA) at 37°C for another 3 hours,

washed and observed under fluorescent microscope. Worms with internal red fluorescence were scored as feeding larvae. For $\Delta 7$ -DA levels, worms were suspended in M9 buffer at 4000 larvae/ml and treated for the indicated times. $\Delta 7$ -DA levels were then analyzed by UPLC-MS as described above.

QPCR

QPCR was performed by SYBR green method as reported (Wang et al., 2015). Briefly, 10,000-20,000 L3i larvae were pelleted and RNA extracted with RNA-STAT60 reagent (Amsbio, Cambridge, MA). Total RNA was digested with Turbo-DNAase (Ambion Inc., Austin, TX) and purified with RNeasy Mini Kits (Qiagen, Germantown, MD) to remove genomic DNA. Following reverse transcription, *Ss-cyp22a9* and *Ss-18S rRNA* levels were analyzed by QPCR (primer sequences in Table S3) and presented as relative mRNA levels (*Ss-cyp22a9*/*Ss-18S rRNA*).

Immunoblotting

Western immunoblotting was performed following standard protocol. Sf9 cells expressing *Ss*-CYP450 enzymes were pelleted and lysed in Laemmli sample buffer by sonication followed by 5 min in a boiling water bath and 2 min on ice. The samples were then analyzed by 10% SDS-PAGE transferred to nitrocellulose membrane, and immunoblotted with the mouse anti-HA antibody [HA.C5] (Abcam, Cambridge, MA) followed by HRP-conjugated anti-mouse antibody (Abcam, Cambridge, MA). The membranes were then imaged by ImageQuant LAS4000 luminescent Image Analyzer (GE Healthcare, Chicago, IL) following an incubation with ECL chemiluminescent substrate reagent kit (ThermoFisher, Waltham, MA).

CRISPR gene disruption

To knock out expression of the gene encoding the DAF-9 ortholog, *Ss-cyp22a9*, CRISPR methods developed specifically for *S. stercoralis* were employed as outlined (Figure 5-figure

supplement 1B, C) and previously reported (Cheong et al., 2021; Gang et al., 2017; Lok, 2019). Briefly, an sgRNA targeting *Ss-cyp22a9* was designed by GPP sgRNA Designer (Broad Institute) and CHOPCHOP (<http://chopchop.cbu.uib.no/>). Top candidates with 5'-(N)₁₈GG-3' formats from both designs were compared to the *S. stercoralis* genome (https://parasite.wormbase.org/Strongyloides_stercoralis_prjeb528/Info/Index/) for off-targeting analysis. The sequence 5'-GCTGGGGACTTATGGACAGG-3', was selected as only targeting the *Ss-cyp22a9* locus within the entire *S. stercoralis* genome and cloned into the gRNA vector pML60 (Gang et al., 2017). *Ss-unc-22* sgRNA (gift from Dr. Ellisa A. Hallem, UCLA) was used as a control. CRISPR gene editing was accomplished using both homologous directed repair (HDR) and non-homologous end joining (NHEJ) and vectors as previously published (Gang et al., 2017; Lok, 2019). For HDR, a homology repair template was made by sewing ~500 bp homology arms flanking the Cas9 cutting site at the *Ss-cyp22a9* locus with a GFP expressing cassette (*Sr-eef-1p::GFP::era*, from pPV529) (Figure 5-figure supplement 1C) by fusion PCR. At least fifty free-living females of *S. stercoralis* were microinjected with plasmids expressing sgRNA (60 ng/ul), Cas9 (pPV540, 20 ng/ul) and the homology repair template (10 ng/ul). Injected females were then placed with adult males in the fecal culture as described (Cheong et al., 2021; Gang et al., 2017; Lok, 2019). The F1 progenies from these matings were collected after 7-day fecal culture at 25°C with the Baermann technique. The GFP positive L3i larvae from the F1 progenies were manually picked and treated with 0.5 mM 8-Br-cGMP or 1 μM Δ7-DA in M9 buffer at 37°C for 22 hrs. The feeding behaviors were then visualized as described above and genotyped individually by single worm PCR with the primers listed in Table 3.

In a second set of experiments, NHEJ CRISPR was used to produce enough *Ss-cyp22a9* knock-out worms for detection of endogenous Δ7-DA. As described above, 50 free-living females

of *S. stercoralis* were microinjected with plasmids expressing Cas9 (pPV540, 20 ng/ul) and sgRNAs against *Ss-cyp22a9* or *Ss-unc-22* (60 ng/ul). Following a fecal culture with free-living males at 25°C for 7 days, the resulting L3i larvae were collected by the Baermann technique and treated by 0.5 mM 8-Br-cGMP in M9 buffer for 3 days. Levels of $\Delta 7$ -DA were analyzed by UPLC-MS as described above.

Gerbil models of *S. stercoralis* infection

Uncomplicated and hyperinfection cases of strongyloidiasis were established in Mongolian gerbils (Charles Rivers, Wilmington, MA) as described (Nolan et al., 1993). For uncomplicated strongyloidiasis, gerbils were subcutaneously injected with 1000 L3i *S. stercoralis* larvae. On day 21 post the infection, the gerbils were switched to drinking water containing 5% sucrose (vehicle) or 50 μ M $\Delta 7$ -DA in 5% sucrose. We have found that adding a small amount of sucrose does not affect infection, but ensures animals drink appropriate amounts of drug. Fecal larval numbers were monitored bi-weekly for the next 14 days. To establish hyperinfection, gerbils were infected similarly but MPA (2 mg/gerbil) was injected subcutaneously weekly from the time of infection. After 10 days post-infection to allow time for the hyperinfection to occur, $\Delta 7$ -DA treatment was begun as noted above. Ivermectin (Merial Limited, Duluth, GA) was intraperitoneally injected at 300 ug/kg on day 21 post infection. Since $\Delta 7$ -DA is rapidly turned over in vivo (Patton et al., 2018), administering it at an earlier time point ensured an adequate amount was delivered. Animals were observed daily for irreversible hyperinfection symptoms that indicate imminent lethality, which include lethargy, hunched back, scruffy hair, lack of activity, and reduced drinking. Animals with such symptoms were sacrificed and autopsy performed to determine end-point parasite numbers as described below.

Parasite burden analysis

Parasite numbers in gerbils were determined as described with modifications (Lok, 2007; Nolan et al., 1993; Stoltzfus et al., 2012). For fecal larvae outputs, infected gerbils were housed in wire bottom cages with a layer of dampened paper towel for 8 hrs. Feces (15-20 droppings) were collected and macerated in 0.9% NaCl. The fecal suspension was then filtered through a layer of cheese cloth and an aliquot of the suspension was spotted on NGM plates. After drying, plates were incubated at 37°C for 10 min and living larvae, which leave traces on the plates, were counted and normalized to the feces weight as larvae per gram feces. To determine end-point parasite burden, intestines were cut longitudinally and incubated in 0.9% NaCl supplemented with an antibiotic cocktail (100 units/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml gentamicin) at 37°C for 2-3 hrs. The suspension was then filtered through a layer of cheese cloth and an aliquot of the suspension was spotted on NGM plates. Following drying and 10 min incubation at 37°C, parasitic adults and intestinal L1-L3a larvae were counted. To determine parasite burden of hyperinfected L3+, parenteral tissues were dissected, minced and larvae collected by the Baermann method were counted on watch glasses.

Data analysis

Data were plotted and analyzed by the indicated statistical tests using GraphPad Prism 8 software to obtain p values. When multiple comparisons were involved, pairwise statistical analyses were first performed to obtain p values and then adjusted by the false discovery rate method using the p.adjust function in R to obtain q values (<https://www.R-project.org/>).

REFERENCES

- Albarqi, M. M., Stoltzfus, J. D., Pilgrim, A. A., Nolan, T. J., Wang, Z., Kliewer, S. A., Mangelsdorf, D. J., & Lok, J. B. (2016). Regulation of life cycle checkpoints and developmental activation of infective larvae in *Strongyloides stercoralis* by dafachronic acid. *PLoS Pathog*, 12(1), e1005358. <https://doi.org/10.1371/journal.ppat.1005358>
- Antebi, A., Culotti, J. G., & Hedgecock, E. M. (1998). *daf-12* regulates developmental age and the dauer alternative in *Caenorhabditis elegans*. *Development*, 125(7), 1191-1205. <https://www.ncbi.nlm.nih.gov/pubmed/9477318>
- Antebi, A., Yeh, W. H., Tait, D., Hedgecock, E. M., & Riddle, D. L. (2000). *daf-12* encodes a nuclear receptor that regulates the dauer diapause and developmental age in *C. elegans*. *Genes Dev*, 14(12), 1512-1527. <https://www.ncbi.nlm.nih.gov/pubmed/10859169>
- Ayoade, K. O., Carranza, F. R., Cho, W. H., Wang, Z., Kliewer, S. A., Mangelsdorf, D. J., & Stoltzfus, J. D. C. (2020). Dafachronic acid and temperature regulate canonical dauer pathways during *Nippostrongylus brasiliensis* infectious larvae activation. *Parasit Vectors*, 13(1), 162. <https://doi.org/10.1186/s13071-020-04035-z>
- Basu, D., Mazumder, S., Shi, X., Baydoun, H., Niklas, J., Poluektov, O., Schlegel, H. B., & Verani, C. N. (2015). Ligand transformations and efficient proton/water reduction with cobalt catalysts based on pentadentate pyridine-rich environments. *Angew Chem Int Ed Engl*, 54(7), 2105-2110. <https://doi.org/10.1002/anie.201409813>
- Bethke, A., Fielenbach, N., Wang, Z., Mangelsdorf, D. J., & Antebi, A. (2009). Nuclear hormone receptor regulation of microRNAs controls developmental progression. *Science*, 324(5923), 95-98. <https://doi.org/10.1126/science.1164899>
- Bisoffi, Z., Buonfrate, D., Montresor, A., Requena-Mendez, A., Munoz, J., Krolewiecki, A. J., Gotuzzo, E., Mena, M. A., Chiodini, P. L., Anselmi, M., Moreira, J., & Albonico, M. (2013). *Strongyloides stercoralis*: a plea for action. *PLoS Negl Trop Dis*, 7(5), e2214. <https://doi.org/10.1371/journal.pntd.0002214>
- Buonfrate, D., Bisanzio, D., Giorli, G., Odermatt, P., Fürst, T., Greenaway, C., French, M., Reithinger, R., Gobbi, F., Montresor, A., & Bisoffi, Z. (2020). The Global Prevalence of *Strongyloides stercoralis* Infection. *Pathogens*, 9(6), 468. <https://www.mdpi.com/2076-0817/9/6/468>
- Buonfrate, D., Requena-Mendez, A., Angheben, A., Munoz, J., Gobbi, F., Van Den Ende, J., & Bisoffi, Z. (2013). Severe strongyloidiasis: a systematic review of case reports. *BMC Infect Dis*, 13, 78. <https://doi.org/10.1186/1471-2334-13-78>
- Chen, T. (2008). Nuclear receptor drug discovery. *Curr Opin Chem Biol*, 12(4), 418-426. <https://doi.org/10.1016/j.cbpa.2008.07.001>
- Cheong, M. C., Wang, Z., Jaleta, T. G., Li, X., Lok, J. B., Kliewer, S. A., & Mangelsdorf, D. J. (2021). Identification of a nuclear receptor/coactivator developmental signaling pathway in the nematode parasite *Strongyloides stercoralis*. *Proc Natl Acad Sci U S A*, 118(8). <https://doi.org/10.1073/pnas.2021864118>
- Folch, J., Lees, M., & Sloane Stanley, G. H. (1957). A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem*, 226(1), 497-509. <https://www.ncbi.nlm.nih.gov/pubmed/13428781>
- Gang, S. S., Castelletto, M. L., Bryant, A. S., Yang, E., Mancuso, N., Lopez, J. B., Pellegrini, M., & Hallem, E. A. (2017). Targeted mutagenesis in a human-parasitic nematode. *PLoS Pathog*, 13(10), e1006675. <https://doi.org/10.1371/journal.ppat.1006675>

- Gerisch, B., & Antebi, A. (2004). Hormonal signals produced by DAF-9/cytochrome P450 regulate *C. elegans* dauer diapause in response to environmental cues. *Development*, 131(8), 1765-1776. <https://doi.org/10.1242/dev.01068>
- Gerisch, B., Rottiers, V., Li, D., Motola, D. L., Cummins, C. L., Lehrach, H., Mangelsdorf, D. J., & Antebi, A. (2007). A bile acid-like steroid modulates *Caenorhabditis elegans* lifespan through nuclear receptor signaling. *Proc Natl Acad Sci U S A*, 104(12), 5014-5019. <https://doi.org/10.1073/pnas.0700847104>
- Hammell, C. M., Karp, X., & Ambros, V. (2009). A feedback circuit involving let-7-family miRNAs and DAF-12 integrates environmental signals and developmental timing in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A*, 106(44), 18668-18673. <https://doi.org/10.1073/pnas.0908131106>
- Hu, P. J. (2007). Dauer. *WormBook*, 1-19. <https://doi.org/10.1895/wormbook.1.144.1>
- Jia, K., Albert, P. S., & Riddle, D. L. (2002). DAF-9, a cytochrome P450 regulating *C. elegans* larval development and adult longevity. *Development*, 129(1), 221-231. <https://www.ncbi.nlm.nih.gov/pubmed/11782415>
- Kerlin, R. L., Nolan, T. J., & Schad, G. A. (1995). Strongyloides stercoralis: histopathology of uncomplicated and hyperinfective strongyloidiasis in the Mongolian gerbil, a rodent model for human strongyloidiasis [corrected]. *Int J Parasitol*, 25(4), 411-420. [https://doi.org/10.1016/0020-7519\(94\)00154-g](https://doi.org/10.1016/0020-7519(94)00154-g)
- Krolewiecki, A. J., Lammie, P., Jacobson, J., Gabrielli, A. F., Levecke, B., Socias, E., Arias, L. M., Sosa, N., Abraham, D., Cimino, R., Echazu, A., Crudo, F., Vercruysse, J., & Albonico, M. (2013). A public health response against *Strongyloides stercoralis*: time to look at soil-transmitted helminthiasis in full. *PLoS Negl Trop Dis*, 7(5), e2165. <https://doi.org/10.1371/journal.pntd.0002165>
- Li, T. M., Chen, J., Li, X., Ding, X. J., Wu, Y., Zhao, L. F., Chen, S., Lei, X., & Dong, M. Q. (2013). Absolute quantification of a steroid hormone that regulates development in *Caenorhabditis elegans*. *Anal Chem*, 85(19), 9281-9287. <https://doi.org/10.1021/ac402025c>
- Lok, J. B. (2007). *Strongyloides stercoralis*: a model for translational research on parasitic nematode biology. *WormBook*, 1-18. <https://doi.org/10.1895/wormbook.1.134.1>
- Lok, J. B. (2019). CRISPR/Cas9 mutagenesis and expression of dominant mutant transgenes as functional genomic approaches in parasitic nematodes. *Front Genet*, 10, 656. <https://doi.org/10.3389/fgene.2019.00656>
- Long, T., Alberich, M., Andre, F., Menez, C., Prichard, R. K., & Lespine, A. (2020). The development of the dog heartworm is highly sensitive to sterols which activate the orthologue of the nuclear receptor DAF-12. *Sci Rep*, 10(1), 11207. <https://doi.org/10.1038/s41598-020-67466-9>
- Ma, G., Wang, T., Korhonen, P. K., Young, N. D., Nie, S., Ang, C. S., Williamson, N. A., Reid, G. E., & Gasser, R. B. (2019). Dafachronic acid promotes larval development in *Haemonchus contortus* by modulating dauer signalling and lipid metabolism. *PLoS Pathog*, 15(7), e1007960. <https://doi.org/10.1371/journal.ppat.1007960>
- Mahanti, P., Bose, N., Bethke, A., Judkins, J. C., Wollam, J., Dumas, K. J., Zimmerman, A. M., Campbell, S. L., Hu, P. J., Antebi, A., & Schroeder, F. C. (2014). Comparative metabolomics reveals endogenous ligands of DAF-12, a nuclear hormone receptor, regulating *C. elegans* development and lifespan. *Cell Metab*, 19(1), 73-83. <https://doi.org/10.1016/j.cmet.2013.11.024>

- Milder, J. E., Walzer, P. D., Kilgore, G., Rutherford, I., & Klein, M. (1981). Clinical features of *Strongyloides stercoralis* infection in an endemic area of the United States. *Gastroenterology*, 80(6), 1481-1488. <https://www.ncbi.nlm.nih.gov/pubmed/7227772>
- Moloo, A. (2020, Dec., 17, 2020). A parasitic infection that can turn fatal with administration of corticosteroids. *WHO News*. <https://www.who.int/news/item/17-12-2020-a-parasitic-infection-that-can-turn-fatal-with-administration-of-corticosteroids>
- Motola, D. L., Cummins, C. L., Rottiers, V., Sharma, K. K., Li, T., Li, Y., Suino-Powell, K., Xu, H. E., Auchus, R. J., Antebi, A., & Mangelsdorf, D. J. (2006). Identification of ligands for DAF-12 that govern dauer formation and reproduction in *C. elegans*. *Cell*, 124(6), 1209-1223. <https://doi.org/10.1016/j.cell.2006.01.037>
- NationalResearchCouncil. (2011). *Guide for the Care and Use of Laboratory Animals: Eighth Edition*. The National Academies Press. <https://doi.org/doi:10.17226/12910>
- Nolan, T. J., Megyeri, Z., Bhopale, V. M., & Schad, G. A. (1993). *Strongyloides stercoralis*: the first rodent model for uncomplicated and hyperinfective strongyloidiasis, the Mongolian gerbil (*Meriones unguiculatus*). *J Infect Dis*, 168(6), 1479-1484. <https://doi.org/10.1093/infdis/168.6.1479>
- Ogawa, A., Streit, A., Antebi, A., & Sommer, R. J. (2009). A conserved endocrine mechanism controls the formation of dauer and infective larvae in nematodes. *Curr Biol*, 19(1), 67-71. <https://doi.org/10.1016/j.cub.2008.11.063>
- Page, W., Judd, J. A., & Bradbury, R. S. (2018). The unique life cycle of *Strongyloides stercoralis* and implications for public health action. *Trop Med Infect Dis*, 3(2). <https://doi.org/10.3390/tropicalmed3020053>
- Patton, J. B., Bonne-Annee, S., Deckman, J., Hess, J. A., Torigian, A., Nolan, T. J., Wang, Z., Kliever, S. A., Durham, A. C., Lee, J. J., Eberhard, M. L., Mangelsdorf, D. J., Lok, J. B., & Abraham, D. (2018). Methylprednisolone acetate induces, and Delta7-dafachronic acid suppresses, *Strongyloides stercoralis* hyperinfection in NSG mice. *Proc Natl Acad Sci U S A*, 115(1), 204-209. <https://doi.org/10.1073/pnas.1712235114>
- Prichard, R. K. (2007). Ivermectin resistance and overview of the Consortium for Anthelmintic Resistance SNPs. *Expert Opin Drug Discov*, 2(s1), S41-52. <https://doi.org/10.1517/17460441.2.S1.S41>
- Repetto, S. A., Ruybal, P., Batalla, E., Lopez, C., Fridman, V., Sierra, M., Radisic, M., Bravo, P. M., Risso, M. G., Gonzalez Cappa, S. M., & Alba Soto, C. D. (2018). Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment. *Clin Infect Dis*, 66(10), 1558-1565. <https://doi.org/10.1093/cid/cix1069>
- Rottiers, V., Motola, D. L., Gerisch, B., Cummins, C. L., Nishiwaki, K., Mangelsdorf, D. J., & Antebi, A. (2006). Hormonal control of *C. elegans* dauer formation and life span by a Rieske-like oxygenase. *Dev Cell*, 10(4), 473-482. <https://doi.org/10.1016/j.devcel.2006.02.008>
- Sharma, K. K., Wang, Z., Motola, D. L., Cummins, C. L., Mangelsdorf, D. J., & Auchus, R. J. (2009). Synthesis and activity of dafachronic acid ligands for the *C. elegans* DAF-12 nuclear hormone receptor. *Mol Endocrinol*, 23(5), 640-648. <https://doi.org/10.1210/me.2008-0415>
- Stoltzfus, J. D., Bart, S. M., & Lok, J. B. (2014). cGMP and NHR signaling co-regulate expression of insulin-like peptides and developmental activation of infective larvae in

- 965 *Strongyloides stercoralis*. *PLoS Pathog*, 10(7), e1004235.
- 966 <https://doi.org/10.1371/journal.ppat.1004235>
- 967 Stoltzfus, J. D., Minot, S., Berriman, M., Nolan, T. J., & Lok, J. B. (2012). RNAseq analysis of
- 968 the parasitic nematode *Strongyloides stercoralis* reveals divergent regulation of canonical
- 969 dauer pathways. *PLoS Negl Trop Dis*, 6(10), e1854.
- 970 <https://doi.org/10.1371/journal.pntd.0001854>
- 971 Viney, M. E., & Lok, J. B. (2015). The biology of *Strongyloides* spp. *WormBook*, 1-17.
- 972 <https://doi.org/10.1895/wormbook.1.141.2>
- 973 Wang, Z., Schaffer, N. E., Kliever, S. A., & Mangelsdorf, D. J. (2017). Nuclear receptors:
- 974 emerging drug targets for parasitic diseases. *J Clin Invest*, 127(4), 1165-1171.
- 975 <https://doi.org/10.1172/JCI88890>
- 976 Wang, Z., Stoltzfus, J., You, Y. J., Ranjit, N., Tang, H., Xie, Y., Lok, J. B., Mangelsdorf, D. J.,
- 977 & Kliever, S. A. (2015). The nuclear receptor DAF-12 regulates nutrient metabolism and
- 978 reproductive growth in nematodes. *PLoS Genet*, 11(3), e1005027.
- 979 <https://doi.org/10.1371/journal.pgen.1005027>
- 980 Wang, Z., Zhou, X. E., Motola, D. L., Gao, X., Suino-Powell, K., Conneely, A., Ogata, C.,
- 981 Sharma, K. K., Auchus, R. J., Lok, J. B., Hawdon, J. M., Kliever, S. A., Xu, H. E., &
- 982 Mangelsdorf, D. J. (2009). Identification of the nuclear receptor DAF-12 as a therapeutic
- 983 target in parasitic nematodes. *Proc Natl Acad Sci U S A*, 106(23), 9138-9143.
- 984 <https://doi.org/10.1073/pnas.0904064106>
- 985 Wollam, J., Magner, D. B., Magomedova, L., Rass, E., Shen, Y., Rottiers, V., Habermann, B.,
- 986 Cummins, C. L., & Antebi, A. (2012). A novel 3-hydroxysteroid dehydrogenase that
- 987 regulates reproductive development and longevity. *PLoS Biol*, 10(4), e1001305.
- 988 <https://doi.org/10.1371/journal.pbio.1001305>
- 989 Wollam, J., Magomedova, L., Magner, D. B., Shen, Y., Rottiers, V., Motola, D. L., Mangelsdorf,
- 990 D. J., Cummins, C. L., & Antebi, A. (2011). The Rieske oxygenase DAF-36 functions as
- 991 a cholesterol 7-desaturase in steroidogenic pathways governing longevity. *Aging Cell*,
- 992 10(5), 879-884. <https://doi.org/10.1111/j.1474-9726.2011.00733.x>
- 993 Yamawaki, T. M., Berman, J. R., Suchanek-Kavipurapu, M., McCormick, M., Gaglia, M. M.,
- 994 Lee, S. J., & Kenyon, C. (2010). The somatic reproductive tissues of *C. elegans* promote
- 995 longevity through steroid hormone signaling. *PLoS Biol*, 8(8).
- 996 <https://doi.org/10.1371/journal.pbio.1000468>
- 997 Zhao, L., Zhou, S., & Gustafsson, J. A. (2019). Nuclear Receptors: Recent Drug Discovery for
- 998 Cancer Therapies. *Endocr Rev*, 40(5), 1207-1249. <https://doi.org/10.1210/er.2018-00222>

ACKNOWLEDGMENTS

We thank members of the Mango/Kliewer lab and Dr. Jeffrey McDonald (UT Southwestern) for fruitful discussions. We thank Dr. Elissa Hallem (UCLA) for providing CRISPR plasmids. We thank Adeiye Pilgrim (Emory) for assistance with cloning. This work was supported by the National Institutes of Health (grant AI105856 to J.B.L., D.J.M. and S.A.K., R01GM141088 to T.Q., and AI050886 to J.B.L), the Robert A. Welch Foundation (grants I-1275 to D.J.M., I-1558 to S.A.K., and I-2010-20190330 to T.Q.), UT Southwestern Eugene McDermott Scholarship (T.Q.), and the Howard Hughes Medical Institute (D.J.M.).

AUTHOR CONTRIBUTIONS

Z.W., J.B.L., S.A.K. and D.J.M. conceived and designed the study. J.B.L., S.A.K. and D.J.M. supervised the study. Z.W., M.C.C., J.D.C.S. and T.G.J. performed experiments. T.G.J and X.L. generated parasite material. J.T, H.D., and T.Q. optimized the synthesis and provided dafachronic acids. Z.W., J.B.L., S.A.K. and D.J.M. wrote the manuscript with contributions from all authors.

DECLARATION OF INTERESTS

The authors declare no competing interests.